Antibody Targeted Amanitin Conjugates (ATAC)

Time: 5:15 pm


• Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin
• Understand how this payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
• Learn more about this technology platform that includes Amanitin supply, site specific conjugation, demonstrated safety profile and biomarker
• Gain insights into HDP-101;The first ATAC directed against BCMA entering Phase I trials in 2020